More Videos
SPECIAL REPORT
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Banks With The Biggest Exposure to The UAE
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
Rick Lee Heart Stent |
]drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4. The question now is whether the FDA will make a move before the July 4th holiday. Any bets?
Speaking of stents, a folo-up to my post last week on the analyst report saying that Boston Scientific [BSX
Loading...
()
]is discounting its drug-coated stent when they're bought along with other medical devices the company makes. At first, a BSX spokesman told me the company doesn't publicly talk about such alleged deals. But then Paul Donovan sent me another email last night asking in the subject line, "What were you smoking?" He took me to task for repeating "an unsubstantiated claim we're (BSX) selling stents for $1,100. We sell stents for about double that, and often more."
And as long as we're on the subject of corporate communications I wanted to pass along this anecdote about yesterday's Alzheimer's drug news out of Myriad Genetics[MYGN
Loading...
()
]. My producer, Ruth, had been working with their people to make sure we were in the loop when the biotech company released the highly anticipated late-stage test results. But the relationship-building groundwork was all for naught.
The press release went out before the opening bell on Monday, but we got no heads up or even an email once the release went out to make sure we saw it. I was out of pocket on assignment in Washington, DC, but reachable--as always--via BlackBerry. When Ruth queried the MYGN point-person about the oversight he replied, "We were planning personal outreach to you on positive results. Then when we found out the results were negative, no one thought to make sure you were on the email distribution list."
Oh, and I wasn't smoking anything when I wrote the BSX post. Aside from what I think was a contact high during my freshman year in the USC Trojan Marching Band on a bus returning from a gig, I've never inhaled.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes